in vitro PHARMACOLOGY 2011 CATALOG - Cerep
in vitro PHARMACOLOGY 2011 CATALOG - Cerep
in vitro PHARMACOLOGY 2011 CATALOG - Cerep
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
200 <strong>in</strong> <strong>vitro</strong> pharmacology <strong>2011</strong> catalog<br />
❚ <strong>Cerep</strong> standard profiles<br />
❚ P-gp mediated drug-drug <strong>in</strong>teraction profile [14 assays]<br />
FULL panel<br />
Ref. P21<br />
Q 4 weeks<br />
MODULES<br />
Module 1 Ref. P21-m1<br />
Q 4 weeks<br />
Module 2 Ref. P21-m2 <br />
Q 4 weeks<br />
P-glycoprote<strong>in</strong> (P-gp) is an efflux pump located <strong>in</strong> the <strong>in</strong>test<strong>in</strong>e and blood-bra<strong>in</strong> barrier among<br />
other tissues. Compounds that are substrates for P-gp may be secreted back <strong>in</strong>to the lumen of<br />
the <strong>in</strong>test<strong>in</strong>e. Additionally, compounds may be <strong>in</strong>hibitors of P-gp, and <strong>in</strong>terfere with the efflux<br />
of concurrently adm<strong>in</strong>istered drugs, result<strong>in</strong>g <strong>in</strong> potentially toxic levels and severe side effects.<br />
Compounds that are P-gp substrates may or may not <strong>in</strong>hibit P-gp activity. Similarly, compounds<br />
that are P-gp <strong>in</strong>hibitors may or may not be substrates for P-gp.<br />
The FDA draft guidance for <strong>in</strong>dustry on drug <strong>in</strong>teraction studies addresses study design and data<br />
analysis for evaluat<strong>in</strong>g P-gp substrates and <strong>in</strong>hibitors. It recommends the bi-directional transport<br />
assay as the def<strong>in</strong>itive assay for identify<strong>in</strong>g P-gp substrates and <strong>in</strong>hibitors s<strong>in</strong>ce this measures<br />
drug efflux <strong>in</strong> a more direct manner than other methods.<br />
The P-gp-mediated drug-drug <strong>in</strong>teraction profile is a set of assays designed to comply with<br />
the FDA draft guidance recommendations.<br />
The P-gp mediated drug-drug <strong>in</strong>teraction profile conta<strong>in</strong>s 2 modules:<br />
1 P-gp substrate evaluation (12 assays):<br />
Step I assays are designed to assess a compound's non-specific b<strong>in</strong>d<strong>in</strong>g and determ<strong>in</strong>e the<br />
efflux ratio and l<strong>in</strong>ear flux range.<br />
Step II assays are designed to confirm whether the efflux activity is related to P-gp by <strong>in</strong>clud<strong>in</strong>g<br />
P-gp <strong>in</strong>hibitors and to evaluate the concentration dependence of the test compound.<br />
2 P-gp <strong>in</strong>hibitor evaluation (2 assays):<br />
Assays are designed to determ<strong>in</strong>e the IC 50 value of the test compound.<br />
For list of assays <strong>in</strong>cluded <strong>in</strong> standard profiles and updated <strong>in</strong>formation:<br />
❚ Please go to www.cerep.com catalog onl<strong>in</strong>e or contact us at sales@cerep.com<br />
❚ Europe: +33 (0)5 49 89 30 00 – USA: +1 (425) 895 8666 – Japan: +81 (0)3 3354 4026 – Ch<strong>in</strong>a: +86 21 5132 0568<br />
New profile Profile/module changed as compared to 2010: please go to www.cerep.com Q Standard turnaround time